AGP Executive Report
Last update: 4 hours agoBiotech Deal: Innate Pharma and Sobi struck a strategic partnership to license lacutamab and enable the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma, a key step toward accelerated approval in Sézary syndrome. Ophthalmology & Access: A Medicare analysis found anti-VEGF drug use varies between fee-for-service and Medicare Advantage plans, with aflibercept leading in FFS and bevacizumab in MA. New Eye Products: Harrow relaunched Byooviz, a ranibizumab biosimilar, and Nicox’s China partner Ocumension filed an NDA for NCX 470 to lower intraocular pressure in open-angle glaucoma. Policy & Safety: Cairo pharmacists urged clearer, legible prescriptions and wider electronic prescribing to cut medication errors. Global Health Workforce: Kyrgyzstan plans to staff medical points and a mobile hospital for the VI World Nomad Games, using 600+ specialists. Health Systems & Medicines: Zimbabwe’s local pharma lobby warned public procurement is too low for domestic manufacturers to scale. Politics & Care: Malaysia’s PM Anwar Ibrahim is undergoing medical tests and procedures and will be observed for two days.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.